Navigation Links
New Data Demonstrate Longer-Term Safety Profile of Esbriet®
Date:9/26/2011

ng the third quarter of 2012.

Since 2008, pirfenidone has been marketed in Japan as Pirespa® by Shionogi & Co. Ltd.

Pirfenidone is still under investigation for the treatment of IPF in the United States and has not been approved by the U.S. Food and Drug Administration for this use.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating and ultimately fatal disease characterized predominantly by fibrosis (scarring) in the lungs, hindering the ability for gas exchange in the lungs. IPF is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is two to five years, with a five-year survival rate of approximately 20-40 percent, which makes IPF more rapidly lethal than many cancers, including breast, ovarian and colorectal. An estimated 30,000-35,000 new cases of IPF are diagnosed in Europe each year. Patients diagnosed with IPF are primarily between the ages of 40 and 80, with a median age of 63 years. The disease tends to affect slightly more men than women.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases. In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet and is currently in a Phase 3 clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
2. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
3. Germgard Lighting Demonstrates the Worlds Most Effective Hand Sterilizer to Protect Against Contagion
4. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
5. New Digital Linear Accelerator Control System Demonstrates Treatment Time Savings of Up to 30 Percent
6. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
7. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
8. New Research Demonstrates High Prevalence of Sexually Transmitted Disease Trichomonas Vaginalis and Potential of New Molecular Test to Improve Detection
9. Topaz Pharmaceuticals Ivermectin Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs
10. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
11. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "MEMS Gyroscopes Analog Devices ADIS16136 ... report to their offering. ... tactical grade applications made a lot of progress ... reliability. They are now accepted in high-reliability environments, ...
(Date:12/15/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ... Vena Cava (IVC) Filters - Global Trends, Estimates and ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior ... US$435 million by 2016. The North America ... global value while Europe claims ...
(Date:12/15/2014)... 2014 BerGenBio AS, a biopharmaceutical ... resistant cancers, today announces that it has raised NOK90 ... new and existing investors. BerGenBio will use ... of its pipeline of innovative cancer therapeutics, in particular ... candidate, BGB324, a first-in-class selective Axl kinase inhibitor, which ...
Breaking Medicine Technology:MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2
... Inc. (Nasdaq: AUXL ) today announced that ... 31st Annual Health Care Conference during March 7-9, 2011 ... Chief Financial Officer, is scheduled to present an overview ... a.m. ET on Wednesday, March 9, 2011.   ...
... 2, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced that, ... determination from the NASDAQ Listing Qualifications Panel (the "Panel") ... for an extension to remain listed on The NASDAQ ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 3Nile Therapeutics Receives Positive NASDAQ Panel Decision 2Nile Therapeutics Receives Positive NASDAQ Panel Decision 3
(Date:12/15/2014)... 15, 2014 A recent survey found ... women as impacting skin health and beauty were: “Connections,” ... skin care.” Water and health advocate and radio host ... article describing the survey and the Four C’s.* Kleyne ... every category discussed would benefit from paying attention to ...
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
(Date:12/15/2014)... Beltsville, MD (PRWEB) December 15, 2014 ... and services today released “ Social Media Cheat Sheets ... cultivating a community that drives results on the top ... a marketing program. It helps drive awareness, engagement, and ... conversions. For marketers to make an impact on new ...
(Date:12/15/2014)... 14, 2014 (HealthDay News) -- Expert pilots process visual ... why they make better decisions during landings, a new ... difficult techniques for pilots to master, and 36 percent ... crashes occur during final approach and landing. Researchers ... 12 moderately experienced pilots while they were at the ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device ... North and South America, Europe, the Middle East, Asia ... for its 2015 Medical Device Industry Survey. Each year, ... business and market trends as well as regulatory and ... areas including:, , Overall prospects for ...
Breaking Medicine News(10 mins):Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
... News) -- People are more likely to recall an unpleasant experience ... over than if they expect it to occur again, say researchers. ... enjoyable whether they think they,ll do them again or not. ... they have a bad experience and allow them to be pleasantly ...
... Researchers at St. Michael,s Hospital and the Institute for ... new tool that will help doctors predict the probability of ... study, published in the journal Circulation , found that ... 30 days and one year after an ischemic stroke. An ...
... 2011Canadians living in deprived neighbourhoods are twice as likely to ... Pacific Coast, according to a new study by researchers at ... rates of illness and death are significantly higher in poorer ... plays a big role in how strongly they are affected," ...
... Simply looking at your body reduces pain, according to new research ... Milano-Bicocca, Italy. Published in the journal Psychological ... pain experienced when a hot object touches the skin. ... looked the larger the hand the greater the effect of ...
... HealthDay Reporter , WEDNESDAY, Feb. 9 (HealthDay News) -- Surgery ... cord birth defect known as spina bifida may be most ... groundbreaking -- research suggests. When successful, the surgery could ... not, experts say, since twice as many spina bifida-affected children ...
... FRANCISCO (February 10, 2011) In a study to ... (SMFM) annual meeting, The Pregnancy Meeting , in San ... intake before and during pregnancy does not protect Norwegian ... has been studied as a possible protecting factor against ...
Cached Medicine News:Health News:New online tool predicts probability of death from stroke 2Health News:Coastal Canadians living in high-risk neighborhoods in poorer health: Study 2Health News:Look at your body to reduce pain 2Health News:Fetal Surgery Could Boost Outcomes in Severe Spina Bifida 2Health News:Fetal Surgery Could Boost Outcomes in Severe Spina Bifida 3Health News:Fetal Surgery Could Boost Outcomes in Severe Spina Bifida 4Health News:Study finds that folate does not offer protection against preterm delivery 2
... most powerful isolated ESU on the market with ... the only ESU that allows the surgeon to ... a standard ES pencil. Excalibur Plus PC Patented ... voltage for smooth cutting through various impedance tissues ...
The Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Maddox rod and occluder...
9 inch double ended with one end black and the other end with 49 holes...
Medicine Products: